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1. Introduction 
Potency is the quantitative measurement of biological activity of a product (European 
Medicines Agency (EMA), 2008). Potency provides assurance that production and 
manufacture demonstrate consistency and provides information on stability and 
performance of the product. It also allows correlation with the clinical response and can help 
avoid product failure or toxicity due to the improper dose of the product being 
administered. For biopharmaceutical products such as drugs, growth factors and cytokines, 
vaccines etc., measurement of potency to predict dose has been a routine procedure for 
many years. Cells, on the other hand, are complex living entities that are continuously in 
flux. The potency of cells can change depending on numerous physiological and external 
environmental factors. Yet, with the increased number of cellular therapeutic applications 
and clinical regimen involving numerous cell types, the need to reliably and reproducibly 
measure biological and functional activity to meet the requirements of potency and ensure 
patient safety is of increasing importance (EMA, 2008; U.S. Food and Drug Administration, 
(FDA), 2011). 
Determining the potency of a stem cell therapeutic can be a daunting task, especially if 
knowledge of the system biology, physiology and regulation is limited. In contrast, the 
hematopoietic system has proven to be not only an excellent model for stem cell biology, but 
also a model system for proliferation and differentiation in different applications. One of 
these applications is stem cell transplantation, a procedure that had its origins during the 
1950s, became a quantitative assay in mice in 1961 (Till & McCulloch), and a routine clinical 
procedure in the 1970s (Santos et al. 1972; Thomas et al. 1977; Santos, 1983) Since that time, 
the number of human bone marrow transplantations reached a peak in the late 1990s 
(National Marrow Donor Program (NMDP); Pasquini & Wang, 2010) and has been declining 
to be replaced by alternative stem cell sources derived from mobilized peripheral blood 
(Haas et al. 1990; Koerbling et al. 1990; Sohn et.al. 2002) and umbilical cord blood 
(Broxmeyer et al. 1989; Gluckman et al. 1989).  
Regardless of the tissue source, a successful transplant of stem cells is dependent upon the 
ability of the transplanted stem cells to lodge or “seed” in the bone marrow and begin the 
process of proliferation to produce lineage-specific progenitor cells. These differentiate into 
functionally mature circulating neutrophils, platelets and erythroid cells, the number of 
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which provides information on the time at which engraftment took place. Proper lympho-
hematopoietic reconstitution occurs much later. The ability of the stem cells to engraft is 
dependent upon two primary factors. The first is the status and condition of the patient. The 
second is the proliferation ability and potential of the stem cells prior to being transplanted. 
Proliferation ability is equivalent to the proliferation status of the stem cells at the time of 
testing. This parameter defines stem cell “quality”. Proliferation potential, on the other 
hand, is the capacity or potential of the stem cells to proliferate. For a continuously 
proliferating system such as lympho-hematopoiesis, stem cell potential decreases from the 
most primitive to the most mature stem cells. Thus, the more primitive a stem cell, the 
greater its proliferation potential and therefore its potency. It follows that the primary goal 
of stem cell transplantation is to provide the patient with stem cells that exhibit varying 
degrees of proliferation potential or potency. In this way, the patient can be endowed with 
stem cells that provide both short- (Charbord, 1994; Civin et al. 1996; Leung et al. 1999; 
Zubair et al. 2006) and long-term (Civin et al. 1996; Leung et al. 1999; Zubair et al. 2006; 
Duggan et al. 2000) engraftment and reconstitution. 
A product that is “balanced” to provide the correct amount of short- and long-term stem cell 
engraftment and reconstitution would be the ideal situation. Present technology is not, 
however, capable of measuring or delivering a “balanced” stem cell product. In many cases, 
the donor stem cell product is skewed towards a greater proportion of mature rather than 
primitive stem cells or visa versa. However, it is possible to quantitatively measure both 
stem cell quality and potency of representative stem cell populations to provide a 
reasonably good approximation of the overall quality and potency of the stem cell product. 
These parameters would then predict the potential of the stem cells to engraft and 
reconstitute the system. 
In 2009, the U.S. Food and Drug Administration (FDA, 2009) designated umbilical cord 
blood as a drug because, when transplanted into a patient, it results in systemic effects. The 
consequence of this designation has meant that virtually every aspect from cord blood 
collection to transplantation must be validated and documented according to regulatory 
requirements. Included in this process are the tests and assays to monitor the procedures 
and characterize the product prior to use. Besides histocompatability testing, the most 
important parameter that should be measured just prior to the stem cell product being used 
is potency. The FDA guidance on potency for cellular therapeutic products specifically 
describes the regulations that define a potency assay as compliant (FDA, 2011). A potency 
assay must provide quantitative data demonstrating the biological activity of all “active 
ingredients” specific to the product. In the case of a stem cell product, the “active 
ingredients” are the stem cell themselves. The results must meet pre-defined acceptance 
and/or rejection criteria so that the test results provide information as to whether the 
product can be released for use. In addition, the assay(s) must include reference materials, 
standards and controls, since without these, the necessary validation parameters (accuracy, 
sensitivity, specificity, precision and robustness) cannot be measured and documented. 
The present communication describes an in vitro assay that measures stem cell potency and 
quality and helps define release criteria for hematopoietic products derived from mobilized 
peripheral blood, umbilical cord blood or bone marrow. The assay was designed to comply 
with regulatory requirements. In the 3-step process, all of the data required is accumulated 
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in the initial stem cell culture and measurement step. The data obtained provides a degree of 
stem cell quality and potency assurance that has hitherto not been possible using the 
traditional methods of total nucleated cell count (TNC), viability and viable CD34+ counts, 
which provide no indication of stem cell functionality or growth. To illustrate the steps of 
the assay, a small number of mobilized peripheral blood samples are used to demonstrate 
the procedure for determining potency, quality and release criteria. A larger cohort of 
umbilical cord blood samples is then used to show the applicability of the assay. 
The assay relies on two basic characteristics of stem cells, namely proliferation ability 
(quality) and potential (potency). It had been previously demonstrated that when 
hematopoietic stem cells were stimulated to proliferate in the presence of growth factors 
and cytokines, the intracellular ATP (iATP) concentration increased proportionately to the 
cell concentration plated (Rich & Hall, 2005; Rich, 2007). The steepness or slope of the cell 
dose response was dependent upon the primitiveness and proliferation potential of the 
cells being examined. Stem cells have a greater proliferation potential than lineage-
specific progenitor cells (Botnick e al. 1979). It would therefore be expected that the slope 
of the cell dose response would be steeper for stem cells than progenitor cells. In other 
words, the steeper the slope of the cell dose response, the greater the proliferation 
potential and the greater the potency. This biological phenomenon was incorporated into 
an assay that first estimates the potency ratio for two stem cell populations of a sample 
compared to a reference standard of the same material. The information obtained from the 
initial culture step was then used in the second step to substantiate the correlation 
between stem cell potency and quality. Finally, stem cell potency and quality were 
combined to determine release criteria of a sample. This information is provided when the 
iATP is released after culture by lysis of the cells. The iATP acts as a limiting substrate for 
the most sensitive, non-radioactive signal detection system available. This is a 
luciferin/luciferase reaction that produces bioluminescence, which is measured as light in 
a plate luminometer (Rich, 2003). The procedure and results described in this 
communication lay the foundation for future studies of stem cell potency and clinical 
outcome that might improve the risk of graft failure (Picardi & Arcese, 2010; Querol et al. 
2010) as well as safety and efficacy for the patient.  
2. Materials and methods 
2.1 Cells 
Several cryopreserved, mobilized peripheral blood (mPB) samples from different donors 
were obtained from AllCells, Inc (Berkley, CA) in accordance with the company’s Internal 
Review Board (IRB) approval. Vials of cryopreserved umbilical cord blood (UCB) samples 
were provided and released for research purposes by the University of Colorado Cord 
Blood Bank (ClinImmune, Inc) in Aurora, CO with approval by the respective Internal 
Review Board. Additional mPB and UCB cells were obtained from each source to use as 
internal reference standards. 
2.2 Reference standards (RS) 
The establishment of RSs is an absolute requirement for performing a potency assay. For 
hematopoietic cell-based therapeutics the number of cells obtained from a single donor UCB 
unit, mPB procedure or bone marrow aspirate are limited. This poses severe restrictions on 
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establishing cellular reference standards. From a practical viewpoint, there are two 
alternatives. The first would be to establish multiple aliquots from several different donors 
that could be used as reference standards. Although each batch of RS would be expected to 
exhibit different biological activity and therefore different potency and quality 
characteristics, one batch would be designated as the primary RS. A second (donor specific) 
batch of cells would be tested against the primary RS and designated the secondary RS. 
Similarly, a third batch of cells would be tested against the secondary RS and designated the 
tertiary RS. The most recent batch of cells established as the RS would be used for every day 
testing until a new RS is established and tested. In this way it would always be possible to 
prepare a new RS and compare it against and established RS. The second alternative would 
be to assay a statistically significant number of samples of the same material to establish a 
range and mean/median potency that could be used as a “combined” RS for individual 
samples. This type of RS would take considerable time to establish. It would also require 
multiple laboratories to use the same standardized and validated assay so that results could 
be compared. The advantage would be that a “global” reference standard might be 
established for different cellular products that would allow comparison and calculation of 
potency ratios and quality of samples processed by individual laboratories. Release criteria 
for use in transplantation could also be established. The regulatory requirement for 
reference standards needed to measure cell potency is probably one of the most important 
aspects that has to be addressed by the different cellular therapeutic communities and 
standards organizations. 
For the present study, the first alternative to establish reference standards was used. Cells 
designated as reference standards were prepared by separating the mononuclear cells 
(MNC) by density gradient centrifugation (see below), adjusting the cell concentration so 
that 1 million MNC were prepared in 7.5% DMSO with 10% fetal bovine serum (FBS) and 
medium in 1ml. The cells were frozen in ampoules using an automated rate freezer and 
stored in liquid nitrogen (LN2). 
2.3 Preparation of cells for culture 
Cryopreserved cells were thawed in a 37C water bath and the contents transferred to a tube 
containing 20mL of warmed Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented 
with 10% FBS. After thawing and washing the cells once, followed by resuspension in 1mL 
IMDM and 2% DNase, a cell count was performed on 20L using a cell counter (Z2, Beckman 
Coulter, Brea, CA). Another aliquot of 20L was stained with 7-aminoactinomycin D (7-AAD, 
Beckman Coulter, Brea, CA) and the viability measured by flow cytometry using an EPICS 
XL/MCL flow cytometer (Beckman Coulter, Brea, CA). Samples exhibiting viability below 
85% were not used since cells either demonstrated poor proliferation or did not proliferate. 
The MNCs from each sample were fractionated on density gradient medium (Nycoprep 1.077, 
Axis-Shield, Accurate Chemicals and Scientific, Westbury, NY) by centrifugation for 10 min at 
1,000 x g at room temperature (RT). The cells were washed in IMDM, centrifuged at 300 x g for 
10 min at RT and resuspended in IMDM. This additional step removed the contaminating and 
dead cells and increased the viability to above 90%. Since several internal studies indicated 
that 7-AAD could produce false positive results with respect to cell growth potential (data not 
shown), all samples were assessed for the production of iATP at 2,500, 5,000 and 7,500 
cells/well to substantiate metabolic cell viability and functionality as described below. 
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2.4 In vitro cell culture of 2 stem cell populations to determine potency, quality and 
release criteria 
The instrument-based, ATP bioluminescence assay used to determine potency, quality 
and release (HALO-96 PQR, HemoGenix, Inc, Colorado Springs, CO) has been 
previously described in detail (Hall & Rich, 2009). It is summarized here for 
completeness. In contrast to a previous study using cord blood cells and a 
methylcellulose assay format (Reems et al. 2008), the assay described below is a 
methylcellulose-free, 96-well culture system that incorporates Suspension Expansion 
Culture (SEC) technology (Rich, 2007; Hall & Rich, 2009; Olaharski et al. 2009) for 
detecting both primitive (high proliferative potential stem and progenitor cells, HPP-SP) 
and more mature multipotential hematopoietic stem cells (colony-forming cell 
granulocyte, erythroid, macrophage megakaryocyte, CFC-GEMM). The assay was 
performed as follows. For each sample, the cell concentration was adjusted to 7.5 x 105 
cells/mL and a serial dilution performed in IMDM to produce 5 x 105 and 2.5 x 105 
cells/mL. From each cell dilution, 0.1mL was added to two separate tubes containing 
0.9mL of master mix, one for each stem cell population being determined. After mixing, 
0.1mL of the culture master mix was dispensed into 8 replicate wells of a 96-well plate to 
achieve the final concentrations of 2,500, 5,000 and 7,500 cells/well. The cocktail to 
stimulate CFC-GEMM consisted of erythropoietin, granulocyte-macrophage and 
granulocyte colony-stimulating factor, stem cell factor, thrombopoietin, Flt3-ligand and 
interleukins 3 and 6. The cocktail to stimulate the HPP-SP stem cell population contained 
the same growth factors/cytokines as that for CFC-GEMM, but with the addition of 
interleukins 2 and 7. The plates were incubated for 5 days at 37C in a fully humidified 
incubator containing 5% CO2 and 5% O2 (Rich & Kubanek, 1982). 
2.5 Assay calibration, standardization and sample processing 
Prior to measuring bioluminescence of the samples after culture incubation, an ATP 
standard curve was performed (Rich & Hall, 2005; Reems et al. 2008; Hall & Rich, 2009). 
Serial dilutions from a 10M stock concentration were prepared so that the final dilutions 
were 5, 1, 0.5, 0.1, 0.05, 0.01 and 0.005M. In addition, an IMDM background and high and 
low ATP controls were included. Each dilution was dispensed into 4 wells (0.1mL/well) 
of a 96-well plate. To each well, 0.1 mL of an ATP enumeration reagent containing a lysis 
buffer, luciferin and luciferase was added. The contents were mixed and the plate left to 
incubate for 2 min in a plate luminometer (SpectraMax L, Molecular Devices, Sunnyvale, 
CA) after which the bioluminescence was measured as light (photons). The resulting ATP 
standard curve was then used to automatically interpolate the output of the luminometer 
in relative luminescence units (RLU) into standardized ATP concentrations (M) using the 
instrument software (SoftMax Pro v5.4, Molecular Devices, Sunnyvale, CA). Inclusion of 
high and low controls in addition to the ATP standard curve allowed the assay to be 
calibrated and standardized. After performing the ATP standard curve, the sample 
plate(s) were removed from the incubator and allowed to attain room temperature. 
Thereafter, 0.1mL of the ATP enumeration reagent was dispensed into each well and the 
contents mixed. After 10 min incubation in the instrument or in the dark, the 
bioluminescence was measured and the ATP concentrations automatically interpolated 
from the ATP standard curve. 
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2.6 Assay validation and statistics 
The ATP bioluminescence assay has been previously validated in accordance with 
bioanalytical method validation (FDA, 2001). For this specific application, the assay 
exhibited an accuracy (proportion of correct outcomes) of greater than 90%. Sensitivity 
(proportion of correctly identified positive samples) and specificity (proportion of correctly 
identified negative samples) were determined using receiver operator characteristic (ROC) 
statistics (DeLong et al. 1985) in which the area under the curve (AUC) was determined for 
background (no stimulatory cocktail) versus CFC-GEMM and background versus HPP-SP. 
For the former, the AUC was 0.752 (95% confidence intervals; 0.71-0.8; p < 0.0001), while for 
the latter the AUC was 0.73 (95% confidence intervals; 0.68-0.78, p<0.001). Since the AUC 
must be between 0.5 and 1, the results demonstrated that the assay could differentiate 
between sensitivity and specificity. Assay precision (reliability and reproducibility) was 
performed on background, CFC-GEMM and HPP-SP over a cell dose range from 2,500 to 
10,000 cells/well and demonstrated coefficients of variation (CV) of 15% or less. This was in 
compliance with regulatory requirements (FDA, 2011). Robustness, in this case 
transferability of the assay from one laboratory to another, had been previously reported 
(Reems et al. 2008). The results demonstrated a correlation coefficient (R) between 
laboratories of 0.94 (p<0.001). 
Concentrations of ATP (µM) are provided as the mean ± 1 standard deviation of 8 replicate 
wells. The slope of the 3-point cell dose response was obtained from the linear regression 
using least squares analysis (Prism version 5, GraphPad Software, LaJolla, CA). For 
correlations, the slope of the linear regression, goodness of fit (r2) and correlation coefficient 
(R) are reported. Tests of significance for correlation were performed using the Pearson two-
tailed test with an alpha of 0.05. 
3. Results 
The procedure for determining stem cell potency, quality and release criteria is a 3-step 
process. However, only the first step requires cell culture and provides all the information for 
the remaining steps of the procedure. The culture step involves a 3-point cell dose response for 
two stem cell populations (CFC-GEMM and HPP-SP) for both the RS and samples.  
3.1 Step 1 – Measuring stem cell potency of mobilized peripheral blood 
The first step in the procedure is illustrated in Figure 1. This shows the cell dose responses 
for the mature multipotential stem cell, CFC-GEMM (Figs. 1A and 1B), and the more 
primitive stem cell HPP-SP (Figs. 1C and 1D) from 4 different mPB samples cultured for 5 
(Figs. 1A and 1C) and 7 days (Figs. 1B and 1D).  The graphs demonstrate that an 
approximate 3-fold increase in ATP concentration occurs within 2 days when the incubation 
time is increased from 5 to 7 days. A 7  day incubation period allows for increased assay 
sensitivity as well as the ability to perform the assay to accommodate a work schedule. Since 
the increase is cell dose dependent, it demonstrates that the assay is directly measuring an 
increase in the number of cells as a result of cell proliferation. It should be noted however, 
that although measurements at both 5 and 7 days are on the exponential part of the growth 
curve for both HPP-SP and CFC-GEMM, measurement of proliferation on day 7 will exhibit 
slightly greater coefficients of variation (CVs) and will also include cells that have initiated 
differentiation. On day 5, little or no differentiation occurs (data not shown).  
www.intechopen.com
 Hematopoietic Stem Cell Potency for Cellular Therapeutic Transplantation 
 
389 
 
Fig. 1A and 1B. Measurement of Mobilized Peripheral Blood CFC-GEMM Stem Cell Potency 
on 5 and 7 Days of Culture. 
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Fig. 1C and 1D. Measurement of Mobilized Peripheral Blood HPP-SP  Stem Cell Potency on 
5 and 7 Days of Culture. 
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In addition to the samples, a mPB RS was also included and allows the potency ratio to be 
calculated as follows: 
Potency Ratio = Slope of the sample linear regression / Slope of the RS linear regression. 
The potency ratio therefore provides information on the dose required to obtain the same 
response as the RS. Since the potency of the RS is always 1, samples with a potency ratio less 
than 1 will require larger cell doses to produce the same response, while potency ratios 
greater than 1 will require fewer cells to produce the same response as the RS.  
3.2 Step 2 – The relationship between stem cell potency and quality 
The results in Fig. 1 illustrate two fundamental concepts that are necessary for measuring stem 
cell potency and quality. The first concept is that the slope of the cell dose response should be 
greater for the more primitive stem cells (HPP-SP) than for the mature hematopoietic stem 
cells (CFC-GEMM), since the former have greater proliferation potential than the latter. The 
slope of the cell dose response therefore provides a direct measurement of stem cell 
proliferation potential. The greater the proliferation potential, the greater the potency. Thus, 
the slope of the cell dose response is also a direct measurement of potency. The second 
concept, also illustrated in Fig. 1, shows that as the slope increases at a specific cell dose, there 
is a concomitant increase in ATP concentration. This is a measure of stem cell quality.  
The result of combining these two concepts is shown in Figures 2A and 2B for CFC-GEMM 
and HPP-SP stem cell populations, respectively. The figures show that when the ATP 
concentration at a specific cell dose (in this case 5,000 cells/well) is plotted against the slope of 
the cell dose response linear regression for both stem cell populations cultured for either 5 or 7 
days, there is a direct correlation between stem cell potency and quality. As a result, both stem 
cell potency and quality have to be taken into account to determine if the stem cell product 
conforms to specific, but arbitrary, acceptance values and can therefore be released for use. 
3.3 Step 3 – Using stem cell potency and quality to determine release criteria 
Figure 3A and 3B shows the ability of CFC-GEMM and HPP-SP to proliferate at 5,000 
cells/well after 5 and 7 days of culture, respectively. It had previously been found that, after 
5 days in culture, an ATP concentration below 0.04µM indicated that cells could not sustain 
proliferation. At 7 days, this threshold was increased to 0.12µM. After 5 days of culture, the 
ATP concentration of samples 1 and 2 demonstrated minimal proliferation, but greater than 
the 0.04µM threshold. After 7 days of culture, proliferation of both samples had increased, 
together with samples 3 and 4. If release criteria were based solely on stem cell quality or 
proliferation ability, it would be assumed that all 4 samples might be acceptable for release. 
However, Fig. 2 demonstrates that both stem cell quality and potency have to be considered 
as part of the release criteria. 
Figure 3C shows the cumulative potency ratios of both CFC-GEMM and HPP-SP after 5 
days and 7 days (Fig. 3D) in culture. Since the potency of the CFC-GEMM and HPP-SP 
reference standards is always 1, samples 1 and 2 exhibited potency ratios significantly less 
than the reference standard. In contrast, samples 3 and 4 exhibited both high stem cell 
quality and potency after 5 and 7 days of culture. Based on these results, mPB samples 1 and 
2 would be sub-optimal or rejected, while samples 3 and 4 would be acceptable for use. 
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Fig. 2. Relationship Between Stem Cell Potency and Quality for Mobilized Peripheral Blood 
CFC-GEMM and HPP-SP Detected on Day 5 or 7 of Culture.  
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Fig. 3. Combining Mobilized Peripheral Blood Stem Cell Potency and Quality to Provide 
Release Criteria.  
3.4 Umbilical cord blood stem cell potency, quality and release and the relationship to 
engraftment potential 
A total of 28 UCB samples were analyzed for potency and quality using the same 
procedure described for mPB above, except that all assays were terminated after 5 days 
in culture, rather than performing both 5 and 7 day cultures. A 3-point cell dose response 
was performed for both the CFC-GEMM and HPP-SP stem cell populations and the slope 
of the linear regression was calculated for each cell dose response. The respective 
potency ratio for each CFC-GEMM and HPP-SP sample was then calculated using a UCB 
reference standard that was prepared from cord blood unit cells that did not meet the 
necessary criteria for storage. The slopes and potency ratios for each stem cell population 
are shown in Table 1. Also shown are the reported times to neutrophil and platelet 
engraftment. For one sample (sample 10), insufficient cells were obtained to perform a 
cell dose response for both stem cell populations. In two other samples (samples 18 and 
25), insufficient cells were obtained after thawing to perform a HPP-SP stem cell dose 
response.  
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Sample 
Number 
Slope for 
CFC-
GEMM 
Potency 
Ratio for 
CFC-
GEMM 
Slope for 
HPP-SP 
Potency 
Ratio for 
HPP-SP 
Days to 
Neutrophil 
Engraftment 
(>500/ul) 
Days to 
Platelet 
Engraftment 
(>50k/ul) 
1 2.94E-05 2.91 2.23E-05 0.70 28 237 
2 3.14E-05 3.12 2.19E-05 0.69 14 2 
3 1.41E-05 1.40 1.01E-05 0.31 6 45 
4 2.09E-05 2.07 3.04E-05 0.95 30 49 
5 2.19E-05 2.18 2.59E-05 0.81 17 39 
6 9.28E-06 0.92 1.79E-05 0.56 12 9 
7 2.25E-05 2.23 1.67E-05 0.52 17 45 
8 2.50E-05 2.48 1.48E-05 0.46 22 39 
9 1.52E-05 1.50 9.70E-06 0.30 56 13 
10 IE - IE - 43 103 
11 1.77E-05 1.75 9.39E-06 0.29 34 7 
12 2.83E-05 2.81 1.99E-05 0.62 20 26 
13 1.09E-05 1.08 7.43E-06 0.23 NE NE 
14 8.12E-06 0.81 3.55E-06 0.11 19 183 
15 6.69E-06 0.66 4.77E-06 0.15 31 122 
16 1.26E-05 1.25 1.02E-05 0.32 13 39 
17 1.81E-05 1.80 1.90E-05 0.60 5 40 
18 3.07E-05 3.05 IE - NE NE 
19 2.01E-05 1.99 4.45E-05 1.39 27 38 
20 2.52E-05 2.50 3.18E-05 1.00 22 62 
21 1.54E-05 1.53 3.30E-05 1.03 29 55 
22 2.31E-05 2.29 3.30E-05 1.03 18 23 
23 1.20E-05 1.19 1.70E-05 0.53 28 70 
24 1.63E-05 1.62 2.22E-05 0.70 15 46 
25 1.46E-05 1.45 IE - 26 39 
26 2.12E-05 2.10 2.73E-05 0.85 28 61 
27 1.37E-05 1.35 1.74E-05 0.54 37 126 
28 1.50E-05 1.49 2.16E-05 0.68 114 113 
IE = Insufficient cells to perform cell dose response. NE = No engraftment. 
Table 1. Stem Cell Proliferation Potential / Potency Characteristics and Time to Engraftment 
of 28 Umbilical Cord Blood Samples. 
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Fig. 4. Correlation Between Proliferation Potential (Potency) and Proliferation Ability 
(Quality) for CFC-GEMM and HPP-SP Stem Cells from Umbilical Cord Blood. 
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Figures 4A and 4B show the correlation of ATP concentrations at 5,000 cells/well with the 
slope of the UCB dose response for both CFC-GEMM and HPP-SP stem cell populations. 
The correlation coefficient (R) for HPP-SP was greater than that for CFC-GEMM, but the 
correlation for both stem cell populations was statistically significant (p < 0.001). The 
relationship between stem cell potency and quality is an indication that both parameters 
have to be taken into consideration when defining release criteria. Although stem cell 
quality could be ascertained for sample 10, insufficient cells were available to measure stem 
cell potency. Insufficient cells for samples 18 and 26 were also the reason why potency could 
not be determined for the HPP-SP stem cell population. 
 
Fig. 5. Combining Umbilical Cord Blood Stem Cell Potency and Quality to Provide Release 
Criteria. 
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Figure 5A shows the stem cell quality (proliferation ability at a specific cell dose) and Fig. 
5B, the cumulative stem cell potency ratio (proliferation potential measured as the slope of 
the linear regression of the cell dose response and compared to that of the reference 
standard) for each of the stem cell populations. Samples 18 and 25 only show the potency 
for the CFC-GEMM populations since insufficient cells were available to measure the 
potency of the more primitive HPP-SP population. For 21 of the samples, stem cell quality of 
both populations was greater than the arbitrary ATP concentration cutoff level of 0.04µM, 
below which cells cannot sustain proliferation. The same 21 samples also exhibited a 
cumulative potency above the RS potency of 1. Sample 6 exhibited a CFC-GEMM potency 
below the RS, while sample 13 demonstrated a CFC-GEMM potency slightly greater than 
the RS. However, the additional potency provided by the HPP-SP stem cell populations 
increased the cumulative potency above that of the RS.  
It is now possible to consider the interpretation of the results. Samples 14 and 15 pose an 
interesting anomaly. The CFC-GEMM quality is below the ATP concentration cutoff point 
for both samples and slightly greater than the cutoff point for HPP-SP. However, both 
samples exhibit a cumulative potency below the RS. These results would indicate that both 
sample 14 and 15 would exhibit limited or no engraftment potential. From Table 1, the time 
to neutrophil engraftment for sample 14 was only 19 days while that for sample 15 was 31 
days. Platelet engraftment was 183 and 122 days for sample 14 and 15, respectively. 
Therefore, these two samples did not agree with the reported clinical outcome. Table 1 also 
shows that samples 13 and 18 did not engraft. As described above, sample 13 exhibited a 
CFC-GEMM potency that was in a questionable range and may not have provided the 
necessary short-term engraftment and reconstitution. In contrast, sample 18, appeared to 
exhibit sufficient CFC-GEMM quality and potency, although insufficient cells did not allow 
information to be obtained for the primitive HPP-SP stem cell population. Despite the four 
sample outliers, the assay exhibits an accuracy of greater than 85%. Nevertheless, further 
studies that correlate in vitro data with more detailed clinical outcome for both engraftment 
and reconstitution would be prudent to ascertain a range for both stem cell quality and 
potency that would improve the accuracy of the assay. 
3.5 Correlation between the ATP concentration and TNC, MNC, viability, CD34 
There was no correlation between the ATP concentration for both cord blood stem cell 
populations with either dye exclusion viability or CD34+ counts. This was to be expected 
since neither viability nor CD34 membrane expression are cell functionality or proliferation 
markers. However, ATP concentration did correlate with both the TNC and MNC, but only 
when calculated on a per kilogram patient body weight basis. These results are shown in 
Fig. 6A for TNC and 6B for MNC. In both cases, the ATP concentration was calculated based 
on the patient body weight of the number of cells transplanted. The results in Fig. 6A 
demonstrate that when TNC is used, a strong correlation is obtained for the CFC-GEMM, 
but although still statistically significant, the primitive HPP-SP stem cell population 
exhibited a lower correlation coefficient. In contrast, Fig. 6B shows that the correlation 
between the ATP concentration and the MNC, both based on kilogram body weight, for 
CFC-GEMM and HPP-SP is highly significant with lower variation compared to the TNC 
values. The results clearly demonstrate that the greater the number of cells transplanted, the 
greater the number of stem cells transplanted that can exhibit proliferation ability. However, 
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the results also demonstrates that using the mononuclear cell count rather than total 
nucleated cell count produces a better estimate for the stem cell response. However, cell 
counts alone cannot be used as a potency assay and cannot replace the information and 
value provided by a standardized cell functionality assay. 
 
Fig. 6. Correlation between ATP Concentration as a Measure of Stem Cell Proliferation and 
the Number of Cord Blood Cells Transplanted Expressed as either Total Nucleated Cell 
Counts (TNC) or Mononuclear Cell Counts (MNC)/Kilogram Body Weight. 
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4. Discussion 
For biopharmaceutical products, potency is measured by comparing the dose response to 
that of an established RS (Thorpe et al. 1999; Lansky, 1999; FDA, 2011). For these materials, a 
parallel dose response to that of the RS should be obtained (Thorpe et al, 1999; Gottscalk & 
Dunn, 2005; Jonkman & Sidik, 2009). Lack of parallelism indicates either contamination or a 
different material to that of the RS. When the dose response curves are parallel to the RS, the 
horizontal displacement to the left or right indicates a greater or lower potency, respectively. 
The dose of the compound can be compared and, if necessary, adjusted to that of the 
reference standard. In this way, the same dose can always be used with compound batches 
of different potency. 
Cells, in particular, stem cells, pose significant differences and challenges to this paradigm. 
First, unlike biopharmaceutical products, where relatively large quantities of the material 
would be available to establish several batches of reference standards, it might be extremely 
difficult to establish cell reference standards (Strong et al. 2009; Rayment & Williams, 2010). 
There are several alternatives to establishing reference standards for cell therapeutics that 
have already been discussed above. However, a prerequisite for establishing reference 
standards and to compare results within and between laboratories is the use of a 
standardized and validated assay that is sufficiently robust so that it can be transferred and 
established in different laboratories. Lack of such an assay has been the reason why 
laboratories have not been able to directly compare processing, cryopreservation and 
thawing procedures for hematopoietic and other stem cell therapeutic products prior to use.  
It might be argued that the present study should have been performed in parallel with the 
CFU assay. This has been the functional assay used previously in hematopoietic stem cell 
processing laboratories and is still used by the cord blood community today. More recently, 
the CFU assay has been suggested as a potency assay (Page et al. 2011a, 2011b), in addition 
to other parameters normally measured. These include total nucleated cell count (TNC), 
viability and CD34 membrane expression (FDA, 2009). There were three reasons for not 
performing parallel studies using the CFU assay. First, the ATP bioluminescence assay was 
originally derived from the methylcellulose CFU assay. Unlike the CFU assay, however, the 
ATP assay has undergone several major technical advances culminating in the assay used 
for the present study. It was also previously shown that even the methylcellulose-free 
format used in this study is not only equivalent to the original CFU assay, but is clearly a 
more reliable, reproducible and robust assay (Rich, 2007, Reems et al, 2008). Furthermore, 
lower sensitivity and precision (high variations) of the CFU assay, coupled with the lack of 
standardization (see below), would have resulted in inconclusive results. Second, unlike the 
CFU assay, the ATP assay can and has been validated in compliance with bioanalytical 
regulatory requirements (FDA, 2001). Furthermore, for an assay to be a potency assay, the 
regulatory agencies require demonstration of specific assay characteristics (FDA, 2011). 
Assay validation is just one of these characteristics, but to validate an assay, standards and 
controls are required. The CFU assay lacks standards and controls and cannot be validated 
according to regulatory requirements. Finally, it is often assumed that the CFU assay 
measures proliferation, whereas the CFU assay is actually a clonogenic differentiation assay. 
Proliferation is certainly involved in the formation of hematopoietic colonies. However, the 
colonies produced in methylcellulose are identified and counted by the ability of the cells 
producing the colonies to differentiate and mature. Therefore, the CFU assay detects 
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differentiation ability and/or potential, but does not measure a parameter that directly 
correlates with the stem cell proliferation process. Based on these and other characteristics 
(discussed below), the CFU assay was not considered as a comparison assay for this study. 
Many factors affect the quality and potency of a cellular product. First, proportions of 
different stem cell populations originally present in the umbilical cord blood, their quality 
and potency, are an inherent property of the tissue. Second, the procedures used to collect 
and store the cells prior to processing can affect quality and potency. Third, different stem 
cell processing, cryopreservation and thawing procedures not only affect quality and 
potency, but the proportion of stem cells remaining in the product. Finally, the decision 
process to use a particular product should be based on trusted results that can only be 
obtained from an assay(s) that is quantitative, standardized and validated to measure 
quality and potency of the active stem cell ingredients. 
The stem cell potency assay described above is based on performing a minimum 3-point cell 
dose response and comparing the slope of the resulting linear regression to that of a RS of the 
same material. Comparison of cell dose response slopes to calculate the potency ratio was used 
for two reasons. First, measurement of potency of a biopharmaceutical compound usually 
relies on establishing parallelism between the sample and RS dose response curves. When the 
linear portions of the dose response curve are parallel, not only is this an indication that the 
sample and RS are of the same material, but also allows the potency ratio to be calculated from 
the horizontal displacement between the two dose response curves. If cells, and stem cells in 
particular, exhibit parallel cell dose response curves, this is an indication that both the sample 
and RS stem cells demonstrate a similar “stemness” or primitiveness. The resulting parallel 
displacement indicates a difference, not in potency, but in stem cell number between the 
sample and RS. Since hematopoiesis is a continuously proliferating system and the cells are 
continuously in flux, it follows that very few hematopoietic stem cell samples will exhibit 
exactly the same degree of primitiveness to the cells in the RS. Therefore potency measurement 
by parallelism will not provide a general procedure to calculate the potency ratio. Since an 
assay should show linearity within a specific cell concentration range, measuring the slope of 
the cell dose response not only demonstrates assay linearity characteristics, but also provides a 
direct measurement of stem cell primitiveness and proliferation potential, which in turn, is 
equivalent to stem cell potency. By comparing the slope of the sample cell dose response with 
that of the RS, the potency ratio can be calculated. Depending on the stem cell population 
detected, more primitive stem cells will show a steeper slope to that of mature stem cells. This 
procedure can then be used for any proliferating cell population. A 3-point cell dose response 
is the minimum number of data points that can be used to perform linear regression analysis. 
Although a larger number of points could also be used and would be more accurate, it was 
necessary to take into account that for hematopoietic tissues (and other cellular therapeutic 
products), cell availability is limited. Potency measurement should be performed just prior to 
use, since it is related to the dose that is to be administered. From a practical viewpoint, a cord 
blood potency determination would be performed on the limited number of cells thawed in a 
segment used for confirmatory testing prior to the cord blood unit being transplanted. Several 
publications have shown, using TNC, viability, CD34 and CFU, that segments of 
cryopreserved cord blood used for confirmatory testing are a representative sample of the cells 
in the cord blood unit (Goodwin et al. 2003; Solves et al. 2004, Rodriguez et al. 2005; Page et al. 
2011b). However, in all of these cases, the potency of the active ingredients, i.e. the stem cells, 
were not taken into account. 
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A potency assay requires that all active ingredients be measured (FDA, 2011). This is 
relatively easy for a biopharmaceutical compound, but is impossible for a continuously 
proliferating system such as hematopoiesis. Although a hematopoietic stem cell tissue 
may contain many different cell types, the stem cells are the only cells responsible for 
engraftment and reconstitution. The stem cells are therefore the active ingredients for 
which the potency must be measured. Since the hematopoietic stem cell compartment 
consists of a continuum of stem cells and assays are not yet available to test each and 
every stem cell subpopulation, the regulatory requirement to measure all active 
ingredients, cannot be met at the present time. As an alternative, the quality and potency 
of a minimum of two different stem cell populations have been determined; the primitive 
HPP-SP and the more mature CFC-GEMM stem cell populations. As shown in Fig. 5, the 
potency of a single stem cell population would be insufficient and could lead to a false 
interpretation of the results. As also demonstrated in Fig. 5, even a minimum of two stem 
cell populations may result in a false interpretation, but the accuracy is significantly 
greater than if the potency of only one stem cell population was measured. It is certainly 
possible to reliably and reproducibly measure the quality and potency of more than two 
stem cell populations with present technology. However, this has to be weighed against 
the use of larger numbers of cells and the costs associated with testing. It should also be 
emphasized that potency and quality testing need to be performed on the cryopreserved 
sample intended for use. They provide predictive information for release. It is therefore 
reasonable to pose the question, is it preferable to use more cells for a predictive assay 
that might ensure stem cell functionality, engraftment potential and growth than to use 
fewer cells and not perform any assay? 
In this respect, it is worth returning to the tests and assays presently used to characterize the 
cells in the processing laboratory. These are TNC, viability and viable CD34+ counts. These 
three parameters have been designated as measurements of potency for umbilical cord 
blood (FDA, 2009), despite the fact that they do not comply with the necessary regulations 
for a potency assay, especially since none of the parameters are functional assays and 
measure the active ingredients. Of the three parameters listed above, probably the most 
important is the TNC dose. However, the TNC count includes a large proportion of cells 
that play no role in engraftment. Inclusion of these cells actually results in a dilution of the 
active stem cell ingredients. In contrast to using TNC, removing most of the unnecessary 
cells to produce an MNC fraction that contained the pool of stem cells, it was possible to 
demonstrate that the MNC dose used for transplantation exhibited a greater correlation 
with the ATP dose for both the CFC-GEMM and HPP-SP stem cell populations (Fig. 6). This 
result illustrates that the ATP concentration can be used as a measure of stem cell dose, 
which in turn is related to the potency ratio.  
The potency predicts the dose of the product for the intended use. The potency of a stem cell 
product should predict the dose of stem cells required to achieve engraftment. In other 
words, stem cell potency predicts engraftment potential. This should not be confused with, 
and is not the same as time to engraftment. If the slope of the stem cell linear regression 
dose response curves or the stem cell potency ratios provided in Table 1 is plotted against 
the time to engraftment, no correlation will be obtained. This is because potency is entirely 
dependent upon stem cell proliferation potential, while time to engraftment is dependent 
upon the differentiation and maturation of hematopoietic progenitor cells into neutrophils, 
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platelets and erythrocytes. This is the reason why the presence and number of progenitor 
cell colonies counted in the CFU assay, especially GM-CFC and Mk-CFC, relates to the 
appearance and number of neutrophils and platelets in the circulation of the patient (Page et 
al. 2011a).  
Although the number of UCB transplants has increased almost exponentially since the first 
published UCB transplant in 1989 (Gluckman et al. 1989), approximately 20% of patients 
receiving an unrelated UCB transplant exhibit graft failure (Page et al. 2011a, 2011b). This 
has, in part, been attributed to inadequate UCB potency (Page et al. 2011a, 2011b). Previous 
publications have focused on the need for standardized laboratory procedures (Rich, 1997; 
Wagner E et al. 2006; Brand A et al. 2008). A recent publication by Spellman et al. (2011) 
discusses problems facing the cord blood community and the guidelines and requirements 
for “standardized testing methodologies” to be established. The cell-based, ATP 
bioluminescence assay platform described in this communication to measure both stem cell 
potency and quality and, in addition, help define release criteria, constitutes the next 
generation of assays that addresses all of the necessary requirements including, but not 
limited to, standardized methodology, reproducibility with limited variability between 
testing sites, automated testing outputs, high throughput capability and rapid turnaround 
time.  
5. Conclusions 
It is often the case that an assay will be generic and adapted to fit the intended 
application. The present communication describes an assay that has been specifically 
designed and validated for the purpose of measuring stem cell quality and potency for 
hematopoietic cellular therapeutic products derived from mobilized peripheral blood, 
umbilical cord blood and even bone marrow (data not shown). A similar potency and 
quality assay has also been developed for mesenchymal stem cells. The assays incorporate 
an instrument-based, biochemical marker in the form of ATP, the concentration of which 
is directly proportional to the proliferation ability and potential of the stem cell 
populations being measured. The bioluminescence signal detection system is the most 
sensitive, non-radioactive readout available allowing the assay to incorporate external 
standards and controls. The implementation of a fully compliant potency and quality 
assay specific for hematopoietic stem cell products should not only help standardize cell 
processing procedures, but also reduce the risk of graft failure and improve safety and 
efficacy for the patient. 
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